[{"quiz_id": "20251201T041413890Z_grok-4-0709_seed127", "question_id": "20251201T041413890Z_grok-4-0709_seed127-001", "question": "A 58-year-old man with a history of hypertrophic cardiomyopathy presents with recurrent syncope. Genetic testing reveals a mutation in the MYH7 gene. Echocardiography shows asymmetric septal hypertrophy with a left ventricular outflow tract gradient of 80 mmHg at rest. Despite optimal medical therapy with beta-blockers, he continues to experience symptoms. What is the most appropriate next step in management?", "options": ["Alcohol septal ablation", "Surgical myectomy", "Implantation of a dual-chamber pacemaker", "Addition of disopyramide", "Cardiac resynchronization therapy"], "answer": "D", "answer_index": 3, "explanation": "Addition of disopyramide is the most appropriate next step as it is recommended for symptomatic hypertrophic cardiomyopathy with obstruction refractory to beta-blockers, acting as a negative inotrope to reduce the gradient. Alcohol septal ablation and surgical myectomy are invasive options considered only after failure of medical therapy including disopyramide. Pacemaker implantation and cardiac resynchronization therapy are not first-line for outflow tract obstruction in this context.", "generator_model": "grok-4-0709", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\n    \"analysis\": \"Validity label: K. Verdict on keyed answer: Miskeyed. Key stem clues: hypertrophic cardiomyopathy with obstruction (LVOT gradient 80 mmHg), recurrent syncope, refractory to optimal beta-blocker therapy. The vignette describes a patient with symptomatic obstructive HCM despite beta-blockers, which per major guidelines (ACC/AHA, ESC) warrants escalation to invasive septal reduction therapy (surgical myectomy or alcohol septal ablation) as the next step for severe, drug-refractory cases. Disopyramide is an add-on oral therapy, but its use is typically before or alongside beta-blockers, not as the sole next step after beta-blocker failure in a patient with severe obstruction and syncope. The keyed answer (D) is not the single best answer; option B (surgical myectomy) is the most guideline-supported choice. Main medical accuracy issue: the rationale incorrectly positions disopyramide as the definitive next step after beta-blocker failure, which contradicts standard management algorithms. Minimal fix: Change the key to B (surgical myectomy) and update the rationale to reflect guideline-based escalation to septal reduction therapy for severe, refractory obstructive HCM.\",\n    \"logical_false_reason\": \"K\",\n    \"logical_validity\": false,\n    \"medical_accuracy_score\":  \t\n  \"2\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K. Verdict on keyed answer: Miskeyed. Key stem clues: hypertrophic cardiomyopathy with obstruction (LVOT gradient 80 mmHg), recurrent syncope, refractory to optimal beta-blocker therapy. The vignette describes a patient with symptomatic obstructive HCM despite beta-blockers, which per major guidelines (ACC/AHA, ESC) warrants escalation to invasive septal reduction therapy (surgical myectomy or alcohol septal ablation) as the next step for severe, drug-refractory cases. Disopyramide is an add-on oral therapy, but its use is typically before or alongside beta-blockers, not as the sole next step after beta-blocker failure in a patient with severe obstruction and syncope. The keyed answer (D) is not the single best answer; option B (surgical myectomy) is the most guideline-supported choice. Main medical accuracy issue: the rationale incorrectly positions disopyramide as the definitive next step after beta-blocker failure, which contradicts standard management algorithms. Minimal fix: Change the key to B (surgical myectomy) and update the rationale to reflect guideline-based escalation to septal reduction therapy for severe, refractory obstructive HCM.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed127", "question_id": "20251201T041413890Z_grok-4-0709_seed127-002", "question": "A 4-year-old boy with a history of recurrent urinary tract infections is found to have vesicoureteral reflux on voiding cystourethrogram. Renal ultrasound shows mild hydronephrosis. Despite prophylactic antibiotics, he develops breakthrough infections. Genetic evaluation reveals a mutation in the PAX2 gene. What is the most likely associated syndrome?", "options": ["Denys-Drash syndrome", "Renal coloboma syndrome", "Branchio-oto-renal syndrome", "Alport syndrome", "Frasier syndrome"], "answer": "B", "answer_index": 1, "explanation": "Renal coloboma syndrome is associated with PAX2 mutations, characterized by renal hypoplasia, vesicoureteral reflux, and optic nerve colobomas. Denys-Drash and Frasier syndromes involve WT1 mutations, while Alport syndrome relates to collagen IV defects. Branchio-oto-renal syndrome is linked to EYA1 mutations.", "generator_model": "grok-4-0709", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\n    \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues: recurrent UTIs, vesicoureteral reflux, mild hydronephrosis, breakthrough infections, and a PAX2 gene mutation. The question asks for the syndrome most likely associated with this genetic finding. The vignette is internally consistent and provides a specific, discriminating genetic marker (PAX2). The keyed answer (B, Renal coloboma syndrome) is the only option directly linked to PAX2 mutations, which is a well-established association in medical genetics. All other options are associated with different genes (WT1, EYA1, collagen IV), making them incorrect. No logical contradictions or missing details prevent a unique answer. Medical accuracy is sound. Minimal fix: None required; the item is valid and accurate as written.\",\n    \"logical_false_reason\": \"T\",\n    \"logical_validity\": true,\n    \"medical_accuracy_score\":", "judge_output_valid": false, "judge_parse_error": "json decode error: Expecting value: line 5 column 30 (char 916)"}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed127", "question_id": "20251201T041413890Z_grok-4-0709_seed127-003", "question": "In the emergency department, a 32-year-old woman presents with acute chest pain and dyspnea following a long-haul flight. CT pulmonary angiography confirms a segmental pulmonary embolism. She has a history of oral contraceptive use and a positive family history for thrombophilia. Laboratory testing shows elevated factor VIII levels. What is the most appropriate initial anticoagulant therapy?", "options": ["Low-molecular-weight heparin followed by warfarin", "Direct oral anticoagulant such as rivaroxaban", "Unfractionated heparin with thrombolysis", "Fondaparinux monotherapy", "Aspirin and clopidogrel combination"], "answer": "B", "answer_index": 1, "explanation": "Direct oral anticoagulants like rivaroxaban are preferred for initial treatment of pulmonary embolism in non-pregnant patients without severe renal impairment or active cancer. Low-molecular-weight heparin followed by warfarin is an alternative but less convenient. Thrombolysis is reserved for hemodynamically unstable cases, and antiplatelet therapy is insufficient for venous thromboembolism.", "generator_model": "grok-4-0709", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\n    \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues: acute PE in a non-pregnant, non-cancer patient with provoked risk factors (OCP, flight, family history, elevated factor VIII). The patient is hemodynamically stable (no mention of hypotension or shock). Main logical issue: None. Main medical accuracy issue: None. The vignette is consistent with current ACCP/ESC guidelines where DOACs (e.g., rivaroxaban) are first-line for acute PE in stable patients. Option A is a valid but less preferred alternative. Option C (thrombolysis) is for massive/high-risk PE. Options D and E are incorrect (fondaparinux is not standard monotherapy; antiplatelets are insufficient). Minimal fix: None required; the item is clear and accurate. Adding 'She is hemodynamically stable' would further rule out thrombolysis but is not strictly necessary.\",\n    \"logical_false_reason\": \"T\",\n    \"logical_validity\": true,\n    \"medical_accuracy_score\":", "judge_output_valid": false, "judge_parse_error": "json decode error: Expecting value: line 5 column 30 (char 968)"}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed127", "question_id": "20251201T041413890Z_grok-4-0709_seed127-004", "question": "A 45-year-old woman presents with symmetric polyarthritis, morning stiffness, and a rash on her trunk. Laboratory tests show positive anti-citrullinated protein antibodies and elevated inflammatory markers. Despite methotrexate therapy, her disease progresses. Genetic testing reveals a mutation in the NLRP3 gene. What is the most likely diagnosis?", "options": ["Rheumatoid arthritis", "Cryopyrin-associated periodic syndrome", "Adult-onset Still's disease", "Beh√ßet's disease", "Systemic lupus erythematosus"], "answer": "B", "answer_index": 1, "explanation": "Cryopyrin-associated periodic syndrome involves NLRP3 mutations, presenting with arthritis, rash, and autoinflammatory features that may mimic rheumatoid arthritis but respond poorly to standard DMARDs. Rheumatoid arthritis typically lacks this genetic mutation and responds to methotrexate. Adult-onset Still's disease and others do not feature NLRP3 mutations.", "generator_model": "grok-4-0709", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\n    \"analysis\": \"Validity label: K. Verdict on keyed answer: Miskeyed. Key stem clues: symmetric polyarthritis, morning stiffness, positive anti-CCP antibodies, and elevated inflammatory markers are classic for rheumatoid arthritis (RA). The rash and poor response to methotrexate are atypical but can occur in severe or refractory RA. The mention of an NLRP3 mutation is a major distracter, as it is pathognomonic for cryopyrin-associated periodic syndromes (CAPS), which are autoinflammatory disorders. However, CAPS does not present with anti-CCP antibodies, a highly specific serologic marker for RA. This creates a fundamental contradiction: the stem provides two mutually exclusive diagnostic anchors (anti-CCP for RA, NLRP3 for CAPS). A unique best answer cannot be determined from the conflicting data. Main logical issue: Contradiction (C) due to incompatible diagnostic clues. Main medical accuracy issue: Combining a highly specific RA marker with a definitive CAPS mutation is clinically unrealistic. Minimal fix: Remove either the anti-CCP positivity or the NLRP3 mutation to align the vignette with a single coherent diagnosis.\",\n    \"logical_false_reason\": \"C\",\n    \"logical_validity\": false,\n    \"medical_accuracy_score\":", "judge_output_valid": false, "judge_parse_error": "json decode error: Expecting value: line 5 column 30 (char 1239)"}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed127", "question_id": "20251201T041413890Z_grok-4-0709_seed127-005", "question": "A 28-year-old man with type 1 diabetes mellitus presents with recurrent hypoglycemia despite insulin dose adjustments. Continuous glucose monitoring shows nocturnal hypoglycemia. Laboratory evaluation reveals elevated proinsulin levels and a low C-peptide. What is the most likely underlying mechanism?", "options": ["Insulinoma", "Factitious hypoglycemia from exogenous insulin", "Adrenal insufficiency", "Autoimmune hypoglycemia", "Nesidioblastosis"], "answer": "B", "answer_index": 1, "explanation": "Factitious hypoglycemia from exogenous insulin is indicated by low C-peptide and elevated proinsulin due to suppressed endogenous insulin production. Insulinoma would show high C-peptide and proinsulin. Adrenal insufficiency typically causes hyperglycemia, and autoimmune hypoglycemia involves insulin antibodies with variable C-peptide.", "generator_model": "grok-4-0709", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: K (Miskeyed). Verdict: Miskeyed. Key stem clues: Type 1 diabetes, recurrent hypoglycemia, nocturnal pattern, elevated proinsulin, low C-peptide. The low C-peptide definitively indicates suppressed endogenous insulin secretion, which is consistent with exogenous insulin administration (B) and rules out insulinoma (A) and nesidioblastosis (E), which would have high C-peptide. However, the elevated proinsulin is a critical contradiction: exogenous insulin administration suppresses both endogenous insulin and proinsulin secretion, leading to low proinsulin. The provided lab pattern (elevated proinsulin, low C-peptide) is pathophysiologically impossible for factitious insulin use. This internal contradiction (C) undermines the item. The keyed answer (B) is medically inaccurate given the lab values. Minimal fix: Change 'elevated proinsulin levels' to 'low proinsulin levels' to make factitious insulin (B) the consistent, unique best answer.\",\n  \"logical_false_reason\": \"C\",\n  \"logical_validity\": false,\n  \"medical_accuracy_score\":  \"2\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (Miskeyed). Verdict: Miskeyed. Key stem clues: Type 1 diabetes, recurrent hypoglycemia, nocturnal pattern, elevated proinsulin, low C-peptide. The low C-peptide definitively indicates suppressed endogenous insulin secretion, which is consistent with exogenous insulin administration (B) and rules out insulinoma (A) and nesidioblastosis (E), which would have high C-peptide. However, the elevated proinsulin is a critical contradiction: exogenous insulin administration suppresses both endogenous insulin and proinsulin secretion, leading to low proinsulin. The provided lab pattern (elevated proinsulin, low C-peptide) is pathophysiologically impossible for factitious insulin use. This internal contradiction (C) undermines the item. The keyed answer (B) is medically inaccurate given the lab values. Minimal fix: Change 'elevated proinsulin levels' to 'low proinsulin levels' to make factitious insulin (B) the consistent, unique best answer.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "C", "verdict": "FAIL", "fail_reason": "C"}, "judge_verdict": "FAIL", "judge_fail_reason": "C", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed127", "question_id": "20251201T041413890Z_grok-4-0709_seed127-006", "question": "A 65-year-old man with ischemic cardiomyopathy and an ejection fraction of 25% develops sustained ventricular tachycardia. He is hemodynamically stable. Electrophysiology study identifies a reentrant circuit in the infarct border zone. Despite amiodarone therapy, episodes recur. What is the most appropriate next intervention?", "options": ["Catheter ablation", "Implantable cardioverter-defibrillator upgrade to biventricular", "Addition of mexiletine", "Stellate ganglionectomy", "Cardiac sympathetic denervation"], "answer": "A", "answer_index": 0, "explanation": "Catheter ablation is the most appropriate for recurrent ventricular tachycardia in ischemic cardiomyopathy refractory to antiarrhythmic drugs, targeting the reentrant circuit. ICD upgrade addresses heart failure but not arrhythmia substrate directly. Mexiletine addition is less effective for scar-related VT, and surgical options like ganglionectomy are reserved for refractory cases.", "generator_model": "grok-4-0709", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\n    \"analysis\": \"Validity label: V. Verdict: Correct best. Key stem clues: ischemic cardiomyopathy, EF 25%, sustained VT, hemodynamically stable, reentrant circuit identified, amiodarone failure. The clinical problem is selecting the next intervention for recurrent, scar-related VT after failed antiarrhythmic therapy. The keyed answer (catheter ablation) is the guideline-supported next step for VT ablation in this context, directly targeting the identified substrate. Alternatives are inferior: ICD upgrade (B) is for heart failure, not primary VT control; mexiletine (C) is less effective for scar VT; stellate ganglionectomy (D) and cardiac sympathetic denervation (E) are last-line surgical options. No contradictions or missing critical details. Medical accuracy is sound. Minimal fix: none required; item is logically valid and accurate.\",\n    \"logical_false_reason\": \"T\",\n    \"logical_validity\": true,\n    \"medical_accuracy_score\":", "judge_output_valid": false, "judge_parse_error": "json decode error: Expecting value: line 5 column 30 (char 943)"}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed127", "question_id": "20251201T041413890Z_grok-4-0709_seed127-007", "question": "An 8-year-old girl with short stature and failure to thrive undergoes evaluation. Bone age is delayed, and laboratory tests show low IGF-1 with normal growth hormone stimulation. Genetic testing reveals a mutation in the IGF1R gene. What is the most appropriate management strategy?", "options": ["Recombinant growth hormone therapy", "IGF-1 replacement therapy", "Nutritional supplementation", "Thyroid hormone replacement", "Corticosteroid therapy"], "answer": "B", "answer_index": 1, "explanation": "IGF-1 replacement therapy is indicated for IGF1R mutations causing primary IGF-1 deficiency resistant to growth hormone. Recombinant growth hormone would be ineffective due to receptor defect. Nutritional or hormonal supplements like thyroid or corticosteroids do not address the underlying IGF-1 resistance.", "generator_model": "grok-4-0709", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\n    \"analysis\": \"Validity label: K. Verdict on keyed answer: Miskeyed. The vignette describes a child with short stature, delayed bone age, low IGF-1, normal GH stimulation, and a confirmed IGF1R gene mutation. This constellation is diagnostic of primary IGF-1 deficiency due to IGF-1 resistance. The keyed answer (B, IGF-1 replacement therapy) is not the standard of care; recombinant IGF-1 (mecasermin) is FDA-approved for severe primary IGF-1 deficiency, but its use is highly specialized, often reserved for severe cases, and not universally considered the first-line 'most appropriate management strategy' for all IGF1R mutations. Option A (recombinant growth hormone) is correctly identified as ineffective. However, the stem lacks critical details (e.g., severity, nutritional status, exclusion of other deficiencies) to uniquely justify starting a complex, injectable hormone therapy over a comprehensive evaluation and initial supportive measures (Option C, nutritional supplementation), which is a common first step. This underspecification (U) leads to multiple defensible answers (M). Main medical issue: oversimplification of a nuanced management pathway. Minimal fix: Specify 'severe primary IGF-1 deficiency unresponsive to nutritional optimization' to justify IGF-1 replacement as the clear best answer.\",\n    \"logical_false_reason\": \"K\",\n    \"logical_validity\": false,\n    \"medical_accuracy_score\":", "judge_output_valid": false, "judge_parse_error": "json decode error: Expecting value: line 5 column 30 (char 1417)"}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed127", "question_id": "20251201T041413890Z_grok-4-0709_seed127-008", "question": "In the emergency department, a 50-year-old man presents with severe abdominal pain and vomiting. CT scan shows acute pancreatitis with necrosis. He develops hypotension and acute kidney injury. Serum triglycerides are 1200 mg/dL. What is the most appropriate initial management for the hypertriglyceridemia?", "options": ["Plasmapheresis", "Insulin infusion", "Fibrates", "Niacin", "Statins"], "answer": "B", "answer_index": 1, "explanation": "Insulin infusion effectively lowers triglycerides in hypertriglyceridemic pancreatitis by enhancing lipoprotein lipase activity. Plasmapheresis is reserved for severe cases not responding to insulin. Fibrates, niacin, and statins are long-term therapies not suitable for acute management.", "generator_model": "grok-4-0709", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\n    \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues: acute pancreatitis with necrosis, hypotension, acute kidney injury, and severe hypertriglyceridemia (1200 mg/dL) in an emergency setting. The question asks for the most appropriate initial management for the hypertriglyceridemia. Insulin infusion is the standard acute intervention to rapidly lower triglycerides by activating lipoprotein lipase, aligning with major guidelines. Plasmapheresis is a second-line option for severe or refractory cases. Oral agents (fibrates, niacin, statins) are for chronic control, not acute crisis management. No logical contradictions or missing critical details are present; a single best answer is supported. Medical accuracy is sound. Minimal fix: None required for a valid item; optionally, the stem could specify 'initial' more explicitly to preempt debate about plasmapheresis timing.\",\n    \"logical_false_reason\": \"T\",\n    \"logical_validity\": true,\n    \"medical_accuracy_score\":", "judge_output_valid": false, "judge_parse_error": "json decode error: Expecting value: line 5 column 30 (char 1013)"}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed127", "question_id": "20251201T041413890Z_grok-4-0709_seed127-009", "question": "A 35-year-old woman with seropositive rheumatoid arthritis on infliximab develops fever, weight loss, and lymphadenopathy. Biopsy shows non-caseating granulomas. Serum angiotensin-converting enzyme is elevated. What is the most likely diagnosis?", "options": ["Tuberculosis reactivation", "Infliximab-induced sarcoidosis", "Lymphoma", "Fungal infection", "Amyloidosis"], "answer": "B", "answer_index": 1, "explanation": "Infliximab-induced sarcoidosis is a rare complication of TNF inhibitors, presenting with granulomatous inflammation mimicking sarcoidosis. Tuberculosis would show caseating granulomas and positive cultures. Lymphoma or infections are differentials but less likely without specific evidence.", "generator_model": "grok-4-0709", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: K (Miskeyed). Verdict: Miskeyed. Key stem clues: fever, weight loss, lymphadenopathy, non-caseating granulomas, elevated serum ACE, and history of infliximab therapy. These findings are classic for sarcoidosis. However, the keyed answer (B) introduces a pathophysiologic mechanism (drug-induced) not supported by the vignette, which only states the patient is 'on infliximab.' The most likely diagnosis based on the findings is sarcoidosis, but the stem does not provide evidence to distinguish between de novo sarcoidosis and a drug-induced phenomenon. Option A (Tuberculosis) is incorrect due to non-caseating granulomas and lack of mention of caseation or positive cultures. The logical issue is miskeying: the single best, defensible diagnosis from the findings is sarcoidosis, but the key specifies an unproven etiology. Minimal fix: Change the key to 'Sarcoidosis' or rephrase option B to 'Sarcoidosis' and adjust the stem to include a temporal link to drug initiation if the teaching point is drug-induced disease.\",\n  \"logical_false_reason\": \"K\",\n  \"logical_validity\": false,\n  \"medical_accuracy_score\":  \"3\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (Miskeyed). Verdict: Miskeyed. Key stem clues: fever, weight loss, lymphadenopathy, non-caseating granulomas, elevated serum ACE, and history of infliximab therapy. These findings are classic for sarcoidosis. However, the keyed answer (B) introduces a pathophysiologic mechanism (drug-induced) not supported by the vignette, which only states the patient is 'on infliximab.' The most likely diagnosis based on the findings is sarcoidosis, but the stem does not provide evidence to distinguish between de novo sarcoidosis and a drug-induced phenomenon. Option A (Tuberculosis) is incorrect due to non-caseating granulomas and lack of mention of caseation or positive cultures. The logical issue is miskeying: the single best, defensible diagnosis from the findings is sarcoidosis, but the key specifies an unproven etiology. Minimal fix: Change the key to 'Sarcoidosis' or rephrase option B to 'Sarcoidosis' and adjust the stem to include a temporal link to drug initiation if the teaching point is drug-induced disease.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed127", "question_id": "20251201T041413890Z_grok-4-0709_seed127-010", "question": "A 42-year-old woman with acromegaly undergoes transsphenoidal surgery, but IGF-1 levels remain elevated postoperatively. She declines further surgery. What is the most appropriate pharmacologic therapy?", "options": ["Cabergoline", "Pegvisomant", "Octreotide", "Pasireotide", "Bromocriptine"], "answer": "B", "answer_index": 1, "explanation": "Pegvisomant, a growth hormone receptor antagonist, is the most effective for normalizing IGF-1 in acromegaly resistant to surgery and somatostatin analogs. Octreotide and pasireotide are somatostatin analogs that may not suffice post-surgery. Dopamine agonists like cabergoline or bromocriptine are less potent for pure GH-secreting adenomas.", "generator_model": "grok-4-0709", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict: Correct best. Key stem clues: Acromegaly, failed transsphenoidal surgery, elevated postoperative IGF-1, patient declines further surgery. The question asks for the most appropriate pharmacologic therapy for persistent disease after surgical failure. Pegvisomant is the most effective drug for normalizing IGF-1 in this context, as it directly blocks GH action. The keyed answer (B) is correct. Alternatives are inferior: somatostatin analogs (C, D) are first-line medical therapy but may be insufficient after surgical failure, and dopamine agonists (A, E) are less potent. No internal contradictions or missing critical details. Medical accuracy is sound. Minimal fix: None required; the item is valid and accurate.\",\n  \"logical_false_reason\": \"T\",\n  \"logical_validity\": true,\n  \"medical_accuracy_score\":  \t\n  \"5\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best. Key stem clues: Acromegaly, failed transsphenoidal surgery, elevated postoperative IGF-1, patient declines further surgery. The question asks for the most appropriate pharmacologic therapy for persistent disease after surgical failure. Pegvisomant is the most effective drug for normalizing IGF-1 in this context, as it directly blocks GH action. The keyed answer (B) is correct. Alternatives are inferior: somatostatin analogs (C, D) are first-line medical therapy but may be insufficient after surgical failure, and dopamine agonists (A, E) are less potent. No internal contradictions or missing critical details. Medical accuracy is sound. Minimal fix: None required; the item is valid and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}]